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Aged, 80 years and over
Childhood trauma, selective serotonin reuptake
inhibitors
Cohort studies
A B S T R A C T
Background: Brain-derived neurotrophic factor (BDNF) levels decline during depression and normalise after
remission, although studies in older patient samples are inconsistent. Whether BDNF serum levels predict de-
pression remission is unclear. We hypothesize that the predictive value of serum BDNF levels in late-life de-
pression is moderated by selective serotonin reuptake inhibitors (SSRI) usage and early traumatization.
Methods: Our study sample was a subset of the Netherlands Study of Depression in Older persons (NESDO), a
prospective cohort study. It consisted of 267 older persons with a diagnosis of depression, for which follow-up
data were available. Depression diagnosis was assessed at baseline and follow up using a structured diagnostic
interview (Composite International Diagnostic Interview (CIDI), volume2.1). Logistic regression was performed
(adjusted for covariates) with remission of depression after two years as the dependent variable and baseline
BDNF serum levels, childhood traumatization and SSRI use as independent variables. Results - The mean age of
the subjects was 70.7 years, 65.6% of them were female, their mean BDNF level was 7.7 ng/ml, 80 (30.0%) of
them were traumatised in their childhood,71 (26.6%) used SSRIs and 136 (50.9%) no longer had a depressive
disorder at the two year follow up. The predictive value of BDNF serum levels was conditional on traumatization
and SSRI usage (threeway interaction p= .010). Higher BDNF serum levels predicted remission in traumatized
depressed patients without SSRI usage (OR=1.17, 95% C.I.: 1.00–1.36; p= .048) and in non-traumatized
depressed patients who used SSRIs (OR=1.17, 95% C.I.: 1.00–1.36; p= .052), but not in the other two sub-
groups.
Conclusion: The association between BDNF serum levels and the course of late-life depression seems to depend
on SSRI use and childhood trauma. Based on these results, we hypothesize that childhood trauma may per-
manently reduce (‘blunt’) the responsiveness of the neurotrophic system to SSRI usage, and that this respon-
siveness might be more important for depression course than the actual BDNF serum levels.
1. Introduction
The neurotrophic hypothesis of depression postulates that a stress-
induced reduction of neurotrophic support, predisposes an individual to
depression (Duman et al., 1997). The hypothesis expands further, by
assigning the therapeutic eﬀects of antidepressant medications to their
potency to increase the levels of neurotrophic factors in the brain. One
of the most extensively researched neurotrophins is brain-derived
neurotrophic factor (BDNF) and meta-analyses have indeed shown
lowered serum BDNF-levels in adult depressed patients compared to
non-depressed controls (Bocchio-Chiavetto et al., 2010; Molendijk
et al., 2014; Sen et al., 2008). To our knowledge, ﬁve studies have been
conﬁned to late life depression; three of them found signiﬃcantly
decreased serum BDNF levels (one found decreased plasma BDNF le-
vels) in depressed patients compared to non-depressed controls, (Chu
et al., 2012; Diniz et al., 2010; Laske et al., 2010; Shi et al., 2010),
whereas the ﬁfth study did not (van der Meij et al., 2014)
Whether BDNF serum levels predict depression remission is still
unclear. A few studies have so far shown that BDNF serum levels are
associated with depression remission (Freire et al., 2016; Karege et al.,
2002a; Shimizu et al., 2003; Yoshimura et al., 2010b). However, meta-
analyses concluded that these results need further replication in studies
with larger patient samples (Molendijk et al., 2014; Polyakova et al.,
2015), and that BDNF serum levels may not be suﬃcient to predict
depression remission. We hypothesize that the impact of BDNF on the
course of depression is moderated by selective serotonin reuptake
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inhibitors (SSRI) usage and by early traumatization, as outlined below.
Within the Netherlands Study of Depression and Anxiety (NESDA),
patients with depressive disorders had signiﬁcantly lower BDNF serum
levels compared to non-depressed controls and to remitted patients, and
within the depressed patients, those not using an SSRI had lower BDNF
levels than those using an SSRI (Bus et al., 2015; Molendijk et al.,
2014). Interestingly, nearly all animal studies on BDNF upregulation
have been conducted with SSRIs (Ibrahim et al., 2016; O’Leary et al.,
2009) and in humans, treatment with an SSRI has been found to be a
consistent determinant of depression remission (Cipriani et al., 2018),
also among depressed older patients (Kok et al., 2012; Nelson et al.,
2008; Thorlund et al., 2015). However, in the Netherlands Study of
Depression in Older persons (NESDO), we did not ﬁnd any diﬀerence in
serum BDNF levels between depressed patients and non-depressed
controls (van der Meij et al., 2014), but the depressed patients who
were treated with an SSRI did have signiﬁcantly higher serum BDNF
levels compared to patients using other or no antidepressants (van der
Meij et al., 2014). Furthermore, post-hoc analyses of this SSRI eﬀect
showed that its association was moderated by the presence of childhood
trauma. Increased BDNF serum levels were only found in non-trauma-
tized depressed older patients using an SSRI, and not in traumatized
patients (van der Meij et al., 2014). Based on these ﬁndings, one may
hypothesize that BDNF levels increase by SSRI usage, but that early
traumatization results in a permanent blunting of this responsiveness of
the neurotrophic system across the lifespan. This hypothesis would
oﬀer a biological explanation of why early trauma is consistently as-
sociated with non-remission of depressed patients (Nanni et al., 2012).
The present study aims to examine the predictive value of serum
BDNF levels in late life depression. We hypothesize that: 1) Lower
baseline BDNF serum levels are associated with lower chance of
achieving remission of late-life depression at two-year follow-up, and
2)This eﬀect is moderated by SSRI usage and early traumatization, and
is most pronounced in patients who use an SSRI and did not experience
a childhood trauma.
2. Methods
The present study was performed with data collected for the
Netherlands Study of Depression in Older persons (NESDO). NESDO is a
prospective cohort study with the aim of examining depression in old
age. It speciﬁcally looks into the course of late life depression, its de-
terminants and the impact that late life depression has on the life of the
older individual. The study is approved by the ethical review boards of
the participating institutes. Further details about the NESDO study can
be found in (Comijs et al., 2011).
2.1. Sample
The subjects were between 60 to 93 years of age and were recruited
from mental health institutions and general practitioners in the
Netherlands. A total of 510 older adults were recruited, of which 378
had a depressive disorder during the 6 months before assessment and
132 were non-depressed comparison subjects.
2.2. Inclusion and exclusion criteria
Inclusion criteria for depressed patients were an age of 60 years or
older, a primary diagnosis of a major depressive disorder, dysthymia or
minor depression according to DSM-IV criteria (American Psychiatric
Association, 2000), and being mentally able to give written informed
consent after having received verbal and written information about
NESDO. Persons who had a primary diagnosis of dementia, were sus-
pected for dementia according to the clinician, or had a Mini Mental
State Examination-score (MMSE, Folstein et al., 1975) under 18 (out of
30 points) were excluded. Patients with another primary psychiatric
disease such as bipolar disorder or psychosis were also excluded, as
were, persons with insuﬃcient command of the Dutch language. In- and
exclusion criteria for the non-depressed comparison group were similar,
except that these persons had no lifetime diagnosis of any depressive
disorder.
For the present study, we selected all 378 participants with a de-
pressive disorder in the 6 months before the baseline assessment. From
this group, 111 (29%) patients had to be excluded because they
dropped out before the two-year follow-up interview (n=93, 24.6%),
or had missing data on BDNF at baseline (n=15, 4.0%), or on child-
hood trauma (n=2, 0.5%) or on SSRI usage (n= 1, 0.3%). This re-
sulted in a ﬁnal dataset of 267 patients with complete data on the main
determinants and outcomes. The 111 excluded patients did not diﬀer
from the 267 included patients with respect to any of the primary
variables of interest, i.e. BDNF serum levels at baseline (7.8 (SD=4.5)
versus 7.7 (SD=4.2), p= .870), childhood traumatization (35%
versus 30%, p= .353), or SSRI usage (31% versus 27%, p= .395).
2.3. Data collection
Information was gathered from the participants, regarding their
demographics, mental health outcomes and other physiological and
cognitive characteristics which may inﬂuence the course of depression
(see covariates section). Assessments at baseline and two-year follow-
up included a face-to-face interview, medical examinations, written
questionnaires, cognitive tests and (on baseline only) collection of
fasted blood samples in the morning. All interviews were performed by
well-trained research assistants and were regularly audiotaped for
quality control.
2.4. Primary outcome measure
Depression was assessed using the Composite International
Diagnostic Interview (CIDI; WHO version2.1) at baseline and at two-
year follow-up. The CIDI is a fully structured diagnostic interview
which is designed to assess diagnosis of depression and dysthymia in a
research setting, based on the DSM-IV-TR criteria (Wittchen et al.,
1991). It has a high validity for depressive disorders. Additional ques-
tions were added to the interview to be able to also diagnose minor
depression according to the research criteria of the DSM-IV-TR (Comijs
et al., 2011). At baseline, we also assessed the lifetime prevalence of a
depressive diagnosis with the CIDI.
The presence of a depression diagnosis was deﬁned as major de-
pressive disorder (MDD, n=252) or dysthymia in the past 6 months
(n= 72) or minor depression in the last month (n=16). Note that the
numbers do not add up to 267 as some patients suﬀer from more than
one depressive disorder.
Furthermore, 47 of the patients with an MDD or dysthymia in the
past 6 months before baseline, did not meet the full criteria for a DSM-
IV deﬁned depressive disorder anymore in the last month before
baseline. Since BDNF serum levels were assessed at baseline and these
levels have been shown to correlate with depression severity (Bus et al.,
2012) and treatment response (Yoshimura et al., 2007), we will per-
form sensitivity analyses to check whether the results of our analyses
change when we restrict our sample to the 220 patients whose de-
pressive disorder persisted until the last month before baseline. Our
primary outcome of depression remission was determined from the CIDI
at the two-year follow up assessment, and was deﬁned as the absence of
depression, i.e. of an MDD or dysthymia over the past 6 months and of a
minor depression over the last month (Comijs et al., 2015).
The dichotomous “remission of depression” variable was de-
termined by assigning the value “0″ to the patients who still suﬀered
from depression during follow-up, and the value “1″ to the patients who
no longer suﬀered from depression during follow-up.




BDNF was assessed in serum taken at the baseline assessment. BDNF
serum levels have been used as a marker for BDNF levels in the human
brain, based on the facts that circulating BDNF can cross the blood
brain barrier and strong correlations between serum and brain levels of
BDNF have been found in rats (Karege et al., 2002b). Blood was with-
drawn into vacuum tubes between 07.30 h and 09.30 h after an over-
night fast. No restrictions were enforced on patients with respect to
their medication use before blood withdrawal. Following collection, the
blood was stored at -80 ° Celsius until it was assayed. The Emax Im-
muno Assay system was used according to its manufacturer’s protocol,
by one technician who was blind to the diagnoses and took place in one
laboratory. The assay sensitivity threshold was ascertained at 1.56 ng/
ml (ng/ml), reﬂecting the minimum level of BDNF in the serum that
could be reliably determined.
2.5.2. Early childhood trauma
Childhood trauma was assessed using a structured inventory pre-
viously used in the Netherlands Mental Health Survey and Incidence
Study (de Graaf et al., 2010) and the Netherlands Study of Depression
and Anxiety (Penninx et al., 2008). In this inventory participants are
asked whether they experienced abuse before the age of 16. As report of
childhood abuse might be prone for recall bias with increasing age as
well as in patients experiencing a depression, we speciﬁcally looked at
the presence or absence of physical and/or sexual abuse in line with a
previous cross-sectional report on this topic (van der Meij et al., 2014).
Physical and sexual abuse were found to be consistently reported over
time in patients with personality disorders (Spinhoven et al., 2012) and
meta-analyses have shown that 45–60% of depressed patients meet the
criteria for any personality disorder (Friborg et al., 2014). Physical
abuse included being kicked, hit with or without an object and any
other physical harm. Sexual abuse was deﬁned as being sexually tou-
ched against one’s will or being forced to touch someone sexually. After
an aﬃrmative answer, a question was asked about the frequency of
these events, which was recorded as: Never, once, sometimes, regularly,
often or very often. A dichotomous variable was constructed indicating
the presence of either physical or sexual abuse with patients reporting
either physical or sexual abuse, once or more often.
2.5.3. SSRI usage
Data on medication use were obtained by registration of the medi-
cations the participants brought with them to the interviews.
Medications were registered by name, dosage and frequency of use, and
Anatomical Therapeutical Chemical (ATC) codes were added later.
Antidepressant drugs were classiﬁed in three categories, i.e. selective
serotonin reuptake inhibitors (SSRIs; including N06AB), tricyclic anti-
depressants (TCAs; including N06AA), and other antidepressants (ser-
otonin-norepinephrine reuptake inhibitors (SNRI; including N06AX16,
N06AX21), tetracyclic antidepressants (TeCA; including N06AX03,
N06AX05, and N06AX11).
2.6. Covariates
All characteristics that have been reported previously as potentially
associated with serum BDNF levels were considered as potential con-
founders in the present study and thus included as covariates (Bus et al.,
2011; Molendijk et al., 2014). We considered age, sex, and educational
level (years of education) as potentially important socio-demographic
characteristics.
Additionally, we considered the global level of cognitive functioning
(MMSE; Folstein et al., 1975), the number of chronic somatic diseases
based on self-report and drug use (Kriegsman et al., 1996), season of
blood withdrawal, fasten blood withdrawal (yes/no) and life-style
characteristics like use of alcohol (assessed with Alcohol Use Disorder
Identiﬁcation Test; AUDIT; Bohn et al., 1995), smoking (yes/ no),
physical activity (minutes based on the International Physical Activity
Questionnaire; IPAQ; CRAIG et al., 2003), and body mass index (kg/
m2), since these characteristics are associated with BDNF and mood
(Bus et al., 2011; Molendijk et al., 2011a).
2.7. Statistical analyses
First, baseline characteristics were described for the sample, strati-
ﬁed by the presence of childhood trauma as well as SSRI usage. For
variables that were normally distributed we used the Student t-test to
compare groups and for non-normally distributed variables the Mann
Whitney U test. Categorical variables were compared with the chi-
square test.
Logistic regression was performed, with remission of depressive
disorders at two-year follow-up (yes/no) as the dependent variable and
the three predictor variables as independent variables (i.e. BDNF serum
levels, childhood traumatization, SSRI usage). Each potential con-
founder (see above) was tested on its association with the primary
outcome variable (remitted depression) by logistic regression analysis
with the potential confounder as single independent variable. Variables
associated with the outcome at the 10% level (p < .10) were included
in the ﬁnal multivariate model. The hypothesized moderating eﬀects of
childhood traumatization and SSRI usage were examined by adding the
three-way interaction term of BDNF by childhood traumatization by
SSRI usage to the model, which also included their respective two-way
interaction terms and main eﬀects. In case of signiﬁcance of the three-
way interaction, odds ratios for the eﬀect of BDNF on remission were
calculated stratiﬁed for the presence of childhood traumatization and
SSRI usage.
P-values< 0.05 were considered signiﬁcant. All analyses were




The mean age of the included 267 depressed patients was 70.7 years
(SD 7.5 years) and 176 were female (65.9%). The BDNF variable was
approximately normally distributed (Skewness: 0.59, Kurtosis: 0.28).
The mean BDNF blood serum level was 7.7 ng/ml (SD 4.2 ng/ml). Out
of the 267 patients, 80 (30.0%) reported a history of physical or sexual
childhood abuse. A total of 71 patients (27%) used SSRIs, whereas of
the 196 non-SSRI users, 68 used a TCA, 49 another antidepressant, 4 a
combination of a TCA and another antidepressant, and 75 used no anti-
depressants.
Table 1 presents all the characteristics of the study sample at
baseline, stratiﬁed by the presence of childhood trauma as well as
stratiﬁed by the presence of SSRI-usage. Patients who used an SSRI had
a signiﬁcantly higher IDS baseline sum score, indicating a more severe
depression, than patients not using an SSRI. These patients also had
higher BDNF levels at baseline than non-SSRI users, and somewhat
lower MMSE scores, indicating more cognitive problems. Traumatized
patients also had higher IDS scores at baseline than non-traumatized
patients, were somewhat younger and had more physical problems, as
indicated by more chronic somatic diseases and a higher body mass
index.
3.2. Primary outcome
After 2 years of follow-up, out of the 267 depressed patients at
baseline, 136 (50.9%) had a remission of their depression while 131
(49.1%) were still suﬀering from a depressive disorder.
The unadjusted analyses showed that serum BDNF levels
(OR=1.03; 95% CI: 0.97–1.09; p= .400) as well as SSRI usage
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(OR=0.91; 95% CI: 0.53–1.57; p= .747) were not associated with
remission at follow-up, whereas a history of physical and/or sexual
childhood abuse was related to a lower odds of achieving remission
(OR=0.39; 95% CI: 0.23 – 0.68; p= .001). As shown in Table 2, only
three of the confounders studied were signiﬁcantly associated with
remission at two-year follow-up at the 10% signiﬁcance level. These
were: severity of depressive symptoms at baseline (IDS sum score),
body mass index (BMI), and number of chronic diseases. These three
variables were included as covariates in the multivariate analyses.
In the adjusted analyses - without interaction terms for BDNF,
childhood trauma, and SSRI - BDNF serum levels did not signiﬁcantly
predict depression remission at two-year follow-up (OR=1.03; 95%
CI: 0.97–1.10; p= .346). SSRI usage also did not signiﬁcantly predict
depression remission (OR=1.02; 95% CI: 0.55–1.88; p= .956). The
presence of childhood traumatization, however, did signiﬁcantly pre-
dict depression remission (OR=0.53; 95% CI: 0.29 – 0.95; p= .032).
In the model including interaction terms, the three-way interaction
of BDNF serum level by childhood traumatization by SSRI usage was
found to be statistically signiﬁcant in both the unadjusted (p= .014) as
well as the adjusted (p= .010) analyses. Therefore, analyses were
Table 1
Baseline characteristics of study sample stratiﬁed by childhood traumatization and by SSRI usage.
Childhood trauma SSRI usage
Characteristics No (n= 187) Yes (n=80) p-value No (n= 196) Yes (n= 71) p-value
Demographics:
- Age, years, mean (SD) 71.6 (7.6) 68.9 (7.0) .007 70.8 (7.7) 70.7 (7.1) .975
- Female sex, n (%) 121 (64.7) 54 (67.5) .660 125 (63.8) 50 (70.4) .313
- Education, years, mean (SD) 10.6 (3.4) 10.4 (3.6) .769 10.6 (3.4) 10.2 (3.6) .426
Psychopathology:
- Depression severity (IDS score), mean (SD) 28.1 (12.7) 33.0 (12.8) .004 28.4 (13.0) 33.0 (11.9) .009
- Cognitive functioning (MMSE score), mean (SD) 27.8 (1.8) 28.0 (1.7) .404 28.0 (1.8) 27.5 (1.9) .037
- Use of SSRI, n (%) 50 (26.7) 21 (26.3) .934 – –
- Childhood traumatization, n (%) – – 59 (30.1) 21 (29.6) .934
Blood withdrawal parameters:
- BDNF serum level, mean (SD) 7.7 (4.2) 7.7 (4.1) .937 7.3 (4.2) 8.9 (4.1) .007
- Fasten blood withdrawal, n (%) 180 (96.8) 75 (97.4) .787 185 (96.4) 70 (98.6) .348
- Season of blood withdrawal, n (%) .826 .324
Autumn 39 (20.9) 16 (20.3) 40 (20.5) 15 (21.2)
Winter 37 (19.8) 12 (15.2) 31 (15.9) 18 (25.4)
Spring 55 (29.4) 25 (31.6) 62 (31.8) 18 (25.4)
Summer 56 (29.9) 26 (32.9) 62 (31.8) 20 (28.2)
Lifestyle characteristics:
- Current smoker, n (%) 44 (23.5) 22 (27.5) .491 47 (24.0) 19 (26.8) .642
- Alcohol use (AUDIT score), mean (SD) 2.3 (3.1) 3.2 (4.4) .052 2.6 (3.5) 2.5 (3.5) .739
- Physical activity (IPAQ MET-minutes), mean (SD) 2587 (2450) 2572 (2407) .964 2696 (2501) 2260 (2209) .208
Physical functioning
- No. chronic diseases, mean (SD) 1.9 (1.4) 2.5 (1.7) .002 2.1 (1.5) 2.2 (1.6) .762
- Body Mass Index, kg/m2, mean (SD) 25.6 (3.8) 27.2 (5.3) .006 26.3 (4.3) 25.3 (4.3) .087
Abbreviations: BDNFbrain derived neurotrophin factor; IDSinventory of depressive symptomatology; SSRIselective serotonin re-uptake inhibitor; MMSEmini mental
state examination; SDstandard deviation.
Table 2
Association of baseline characteristics with remission of depression at two-year follow-up.
Co-variates OR [95% CI] p-value
Demographics:
- Age (years) 0.99 [0.96 - 1.02] .454
- Female sex 0.93 [0.56 - 1.55] .791
- Years of education 1.02 [0.95 - 1.09] .666
Psychopathology:
- Depression severity (IDS score) 0.95 [0.93 - 0.97] < .001
- Cognitive functioning (MMSE score) 1.11 [0.97 - 1.27] .138
Blood withdrawal parameters:
- Season of blood withdrawal (summer= reference) .556
Autumn 1.61 [0.74 – 3.52] .226
Winter 1.01 [0.51 – 2.01] .979
Spring 1.23 [0.62 – 2.44] .553
- Fasten blood withdrawal 1.57 [0.37 - 6.69] .545
Lifestyle characteristics:
- Smoker 0.64 [0.36 - 1.11] .112
- Physical activity (IPAQ MET-minutes) 1.00 [1.00 - 1.00] .202
- Alcohol use (AUDIT sum score) 1.02 [0.96 - 1.10] .513
Physical functioning:
- Number of chronic diseases 0.73 [0.61 - 0.87] < .001
- Body Mass Index 0.92 [0.87 - 0.98] .009
Abbreviations: OR, Odds ratio; CI, conﬁdence interval; IDS, inventory of depressive symptomatology; SSRI, selective serotonin re-uptake inhibitor.
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stratiﬁed by childhood traumatization as well as SSRI usage (see
Table 3).
Higher serum BDNF levels were found to predict remission of de-
pression at two-year follow-up with an OR of 1.17 (95% C.I.: 1.00–1.36;
p= .052) among non-traumatized patients using an SSRI and with an
OR of 1.17 (95% C.I.: 1.00–1.36; p= .048) among traumatized patients
not using an SSRI, both after adjustment for covariates (see Table 3). No
relationship between serum BDNF levels and depression remission was
found in non-traumatized patients not using an SSRI or in traumatized
patients using an SSRI.
The sensitivity analyses in the 220 patients whose depressive dis-
order persisted until the last-month before baseline, showed similar
results as for the whole sample. The three-way interaction of BDNF
serum level by childhood traumatization by SSRI usage was again found
to be statistically signiﬁcant in both the unadjusted (p= .041) as well
as the adjusted (p= .023) analyses. The strength of the association
between serum BDNF and depression remission in the adjusted analyses
did not reduce for the non-traumatized patients using an SSRI
(OR=1.18; 95%CI: 1.01–1.39; p= .044) or the traumatized patients
not using an SSRI (OR=1.17; 95%CI: 0.95–1.35; p= .166). Although
it did no longer reach statistical signiﬁcance for the latter group, be-
cause of the reduction in size of this group (from n=59 to n=48).
Again, no relationship between serum BDNF levels and depression re-
mission was found for non-traumatized patients not using an SSRI or for
traumatized patients using an SSRI (OR=0.99; 95%CI: 0.90–1.09;
p= .831, and OR=0.90; 95%CI: 0.70–1.17; p= .440, respectively).
4. Discussion
4.1. Main ﬁndings
In contrast to our ﬁrst hypothesis, higher BDNF serum levels at
baseline were not overall associated with remission of late-life depres-
sion at two-year follow-up. We found that the impact of BDNF serum
levels on remission of late-life depression was moderated by the com-
bination of the presence of early childhood traumatization and SSRI
usage. Higher BDNF serum levels at baseline were associated with a
higher odds on achieving remission at two-year follow-up among two
speciﬁc subgroups, i.e. non-traumatized depressed older patients using
SSRIs and traumatized, depressed older patients not using SSRIs. The
ﬁrst subgroup was the group in which we expected the strongest re-
lationship between baseline BDNF serum levels and depression remis-
sion, based on the reasoning outlined in the Introduction. The positive
ﬁnding in the second subgroup was unanticipated. To understand these
ﬁndings, we will ﬁrst discuss how we hypothesize that BDNF, childhood
traumatization and SSRI usage aﬀect human brain functioning.
4.2. Hypothesized pathophysiological mechanisms
In the adult human brain, neurotrophic factors such as BDNF pro-
mote neuronal survival, induce synaptic plasticity, and modulate the
formation of long-term memories. Animal studies show that early
traumatization may have a long-lasting negative eﬀect on the respon-
siveness of the neurotrophic system (Kuma et al., 2004; Roceri et al.,
2004, 2002; Russo-Neustadt et al., 2001). SSRI usage, on the other
hand, may be thought of as a more contemporary inﬂuence on the
neurotrophic system (Balu et al., 2008; Bus et al., 2011; Molendijk
et al., 2011a; van der Meij et al., 2014). SSRI usage generally stimulates
BDNF expression, but the responsiveness of BDNF to SSRI usage might
be permanently reduced -‘blunted’ one could say- in traumatized pa-
tients (van der Meij et al., 2014). The interaction between these two
mechanisms may explain our ﬁndings, as will be discussed in more
detail below.
In our stratiﬁed analyses, higher BDNF serum levels were found to
be associated with remission of late-life depression among patients with
no childhood trauma history who use an SSRI. Randomized controlled
studies have shown the eﬃcacy of SSRIs in predicting depression re-
mission (Cipriani et al., 2009; Darby-Stewart et al., 2010). We may
hypothesize that BDNF could play a role in the pathway towards de-
pression remission for the following reasons. First, a growing body of
literature shows that SSRIs usage is associated with increased levels of
serum BDNF in depressed individuals, while other types of anti-de-
pressants do not have such a pronounced eﬀect on BDNF (Molendijk
et al., 2011b; Zhou et al., 2017). Secondly, higher baseline serum BDNF
levels in depressed adult patients have been found to be associated with
remission at follow-up as well as with a decrease in depressive symptom
severity (Karege et al., 2002a; Shimizu et al., 2003; Yoshimura et al.,
2010a), although negative ﬁndings have also been reported (Bus et al.,
2015). Finally, one clinical study of 42 depressed patients observed a
signiﬁcant increase in serum BDNF from baseline to after 8 weeks of
treatment in patients who responded to treatment, but not in non-re-
sponders (Yoshimura et al., 2007). However, it is important to state that
all the studies hitherto who reported diﬀerences in serum BDNF levels
between depressive patients and patients who achieved remission, had
small sample sizes (range 19 through 83 patients) and are based on
relatively young patients (mean age of 45 years). Moreover, these stu-
dies did not take childhood traumatization into account. Our ﬁndings
suggest that successful treatment with SSRIs might depend on its ability
to achieve higher BDNF levels, and that this ability is lost or sig-
niﬁcantly reduced in traumatized patients.
We also found that, higher baseline BDNF serum levels are asso-
ciated with remission at two-year follow-up in traumatized depressed
older patients not using an SSRI. Animal studies have consistently
shown that childhood trauma not only reduces hippocampal BDNF
expression acutely (Kuma et al., 2004; Roceri et al., 2004, 2002) but
also chronically (Russo-Neustadt et al., 2001). Although it still remains
debated whether serum BDNF levels correspond to hippocampal BDNF-
expression, studies in rats have shown very high correlations between
both measures (Karege et al., 2002b). Whether the above ﬁndings can
be extended to humans, remains unclear. The general consensus,
however, appears to be that BDNF levels are also reduced in human
adults subjected to early life stressors (Daskalakis et al., 2015). Re-
cently, our group showed that among depressed older patients elevated
BDNF levels were only found among depressed SSRI-users who were not
traumatized during their childhood (van der Meij et al., 2014). This
ﬁnding ﬁts with animal research, which shows that serum BDNF levels
do not respond to SSRIs in traumatized animals (Carboni et al., 2010;
Chourbaji et al., 2011a).
To our knowledge, no studies have examined the impact of early
childhood trauma on BDNF levels in older persons. We hypothesize that
in depressed traumatized patients, serum BDNF levels indicate the
magnitude of the eﬀect of the childhood trauma on the individual, in
the sense that lower BDNF levels represent a more severe eﬀect of the
Table 3
Predictive value of BDNF for depression remission stratiﬁed by childhood
traumatization and SSRI usage.
If N Unadjusted Adjusted*
Trauma SSRI OR [95% CI] p-value OR [95% CI] p-value
No No 137 0.97 [0.89 –
1.05]
.393 0.97 [0.89 –
1.06]
.465
No Yes 50 1.16 [1.00 –
1.35]
.056 1.17 [1.00 –
1.36]
.052
Yes No 59 1.15 [1.00 –
1.31]
.053 1.17 [1.00 –
1.36]
.048
Yes Yes 21 0.91 [0.71 –
1.17]
.448 0.90 [0.70 –
1.17]
.435
Abbreviations: BDNF, brain-derived neurotrophic factor; SSRI, selective ser-
otonin reuptake inhibitor; OR, odds ratio; CI, conﬁdence interval.
* Adjusted for Body Mass Index, Depression severity (IDS sum score), and
number of chronic somatic diseases (i.e. only the covariates associated with the
primary outcome at the 10% level).
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trauma on the older individual and that this reduces their chance to
achieve depression remission. Our ﬁnding that higher baseline BDNF
serum levels in traumatized depressed older patients not using an SSRI
are associated with remission at two-year follow-up, may therefore
indicate that the childhood trauma had a less severe impact on the lives
of these older patients than for those who had lower BDNF levels. Not
ﬁnding this eﬀect in traumatized patients using an SSRI might result
from the opposing eﬀect of SSRI usage on BDNF levels, which neu-
tralizes the negative eﬀect of childhood traumatization on BDNF ex-
pression.
The fact that serum BDNF levels are not associated with remitted
depression in the largest subgroup, i.e. non-traumatized patients not
using an SSRI, is also of interest. While BDNF is thought to be a stress-
related, and potentially causative factor regarding the onset of de-
pression (Chourbaji et al., 2011b; Shadrina et al., 2018), this does not
necessarily imply that BDNF serum levels is a factor strong enough to
inﬂuence the course of depression. In line with our own ﬁndings, ex-
ternal stimulation of BDNF expression (by SSRI usage for instance)
might be necessary for it to have an impact on the course of depression.
4.3. Methodological considerations
For proper interpretation, some limitations of the present study
should be acknowledged. Firstly, BDNF levels were only assessed at
baseline. Therefore, we do not have data on changes in serum BDNF
levels during follow-up. Nonetheless, a study among younger chroni-
cally depressed patients using a similar design showed only minor
variations in BDNF over a two-year follow-up period (Bus et al., 2015).
Secondly, it is also important to mention that data on early childhood
traumatization of the patients were obtained in a retrospective manner.
Arguably it is hard to tell whether this has led to under reporting events
due to memory problems associated with depression (Hickie et al.,
2005) or unwillingness to report embarrassing events(Comijs et al.,
2013) or whether this has led to over reporting due to a cognitive bias
associated with a negative mood (Gerlsma et al., 1990). Two reviews
and one recent study have shown that the impact of these factors is
quite limited (Brewin et al., 1993; Hardt and Rutter, 2004; Mesquita
and Maia, 2018). Moreover, to increase the reliability of our measure of
childhood traumatization, we only included physical or sexual abuse
which we assume to be less susceptible to distorted recall than psy-
chological abuse and emotional neglect. Thirdly, we only studied the
inﬂuence of presence or absence of a childhood traumatization, but
repetitive or continuous traumatization may aﬀect brain neurotrophic
functioning more than a trauma single incident. Fourthly, we did not
have data on the treatment regiments of each patient. Duration of
therapy with a speciﬁc drug, reasons for discontinuation (if any) or
maintaining treatment during the follow-up period are unknown. Fi-
nally, as already mentioned above, we would like to emphasize that
although the interaction term tested was statistically signiﬁcant, in one
of the subgroups the eﬀect of interest did not reach statistical sig-
niﬁcance at the 5% level (with a p-value of .052). This may be due to
the relatively small size of this subgroup (n=50), as some of the other
subgroups. More in general, we can not exclude chance ﬁndings,
especially false negative ﬁndings (i.e. Type II errors), due to limited
statistical power in some of the subgroups. Replication studies in larger
samples are therefore needed to check our ﬁndings.
5. Conclusion
The association between BDNF serum levels and the course of late-
life depression might be better understood by a complex interaction
between enduring eﬀects of early-life traumatization and current SSRI
usage on BDNF serum levels. Based on our results, we hypothesize that
childhood trauma may aﬀect the responsiveness of the neurotrophic
system with respect to SSRI usage. If true, this implies that the re-
sponsiveness of the neurotrophic system is more important than actual
BDNF serum levels. Therefore, we recommend developing paradigms
measuring the responsiveness of the neurotrophic system directly and
implementing these responsiveness measures as mediating mechanisms
into randomized controlled trials on the eﬀectiveness of anti-
depressants, especially SSRIs.
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